Video
Update on adjuvant treatment of bladder cancer
Author(s):
“The bar is high; we want to be curing these patients, not just delaying a recurrence of their cancer,” says Arlene O. Siefker-Radtke, MD.
Video Player is loading.
In this video, Arlene O. Siefker-Radtke, MD, discusses recent developments in the adjuvant treatment of bladder cancer. Siefker-Radtke is a professor of Genitourinary Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston. She was interviewed at the 2022 LUGPA Annual Meeting in Chicago, Illinois.
Related Videos
Gopa Iyer, MD, highlights findings from FORAGER-1 in metastatic urothelial carcinoma
Michael Schweizer, MD, shares data on mevrometostat plus enzalutamide in mCRPC
Laura Bukavina, MD, highlights study of urinary microbiome profiling
Kate Gessner, MD, on the mechanisms of immunotherapy failure in RCC
Darren Feldman, MD, on clinical outcomes in R/R testicular germ cell tumors
ASCO GU recap: Insights on 5 key trials
Laurence Albiges, MD, on COSMIC-313 trial of triplet vs doublet combination in aRCC
Francesca Jackson-Spence, MRCP, on efficacy of savolitinib/durvalumab in papillary renal cancer
Gopa Iyer, MD, on durable efficacy of EV/pembrolizumab in urothelial carcinoma
David Braun, MD, on phase 2 trial of an individualized neoantigen therapy for RCC
Related Content
